Nexien Biopharma, INC
Quarterly Earnings (10-Q)
OTC.Pink
Nexien BioPharma reports its Q3 2025 results, highlighting a net loss and ongoing concerns about the company's ability to continue as a going concern without additional funding.
Worse than expected
Capital raise
OTC.Pink
Nexien BioPharma's Q2 2025 report reveals a net loss and continued concerns about the company's ability to continue as a going concern without additional funding.
Worse than expected
Capital raise
OTC.Pink
Nexien BioPharma's Q3 2024 report reveals a reduced net loss compared to the previous year, but the company faces significant financial challenges and going concern uncertainty.
Worse than expected
Delay expected
Capital raise
OTC.Pink
Nexien BioPharma reports a net loss of $152,599 for the nine months ended March 31, 2024, highlighting ongoing financial challenges and the need for additional capital.
Delay expected
Capital raise
Worse than expected
OTC.Pink
Nexien BioPharma's Q2 2024 report reveals a reduced net loss compared to the previous year, but the company faces significant financial challenges and going concern uncertainty.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
OTC.Pink
Nexien BioPharma's annual report reveals ongoing financial difficulties and a shift towards seeking a business combination, while research and development activities have ceased due to lack of funding.
Delay expected
Capital raise
Worse than expected
Insider Trading (Form 4)
OTC.Pink
Richard S. Greenberg, CEO of Nexien BioPharma, acquired 1,000,000 shares of common stock on May 23, 2024, as compensation for services.
OTC.Pink
Nexien BioPharma's CFO, Evan L. Wasoff, reports acquiring 2,000,000 shares of common stock and discloses holdings of derivative securities.